Pishgar Farhad, Guermazi Ali, Roemer Frank W, Link Thomas M, Demehri Shadpour
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC, Baltimore, MD, 21287, USA.
Department of Radiology, VA Boston Healthcare System, Boston University School of Medicine, Boston, MA, USA.
Eur Radiol. 2021 Jun;31(6):3564-3573. doi: 10.1007/s00330-020-07512-2. Epub 2020 Nov 25.
To evaluate the reliability and validity of measuring subchondral trabecular biomarkers in "conventional" intermediate-weighted (IW) MRI sequences and to assess the predictive value of biomarker changes for predicting near-term symptomatic and structural progressions in knee osteoarthritis (OA).
For this study, a framework for measuring trabecular biomarkers in the proximal medial tibia in the "conventional" IW MRI sequence was developed. The reliability of measuring these biomarkers (trabecular thickness [cTbTh], spacing [cTbSp], connectivity density [cConnD], and bone-to-total volume ratio [cBV/TV]) was evaluated in the Bone Ancillary Study (within the Osteoarthritis Initiative [OAI]). The validity of these measurements was assessed by comparing to "apparent" biomarkers (from high-resolution steady-state MRI sequence) and peri-articular bone marrow density (BMD, from dual-energy X-ray absorptiometry). The association of these biomarker changes from baseline to 24 months (using the Reliable Change Index) with knee OA progression was studied in the FNIH OA Biomarkers Consortium (within the OAI). Pain and radiographic progression were evaluated by comparing baseline WOMAC pain score and radiographic joint space width with the 24-to-48-month scores/measurements. Associations between biomarker changes and these outcomes were studied using logistic regression adjusted for the relevant covariates.
With acceptable reliability, the cTbTh and cBV/TV, but not cTbSp or cConnD, were modestly associated with the "apparent" biomarkers and peri-articular BMD (β: 1.10 [95% CI: 0.45-1.75], p value: 0.001 and β: 3.69 [95% CI: 2.56-4.83], p value: < 0.001, respectively). Knees with increased cTbTh had higher (OR: 1.44 [95% CI: 1.03-2.02], p value: 0.035) and knees with decreased cTbTh (OR: 0.69 [95% CI: 0.49-0.95], p value: 0.026) or decreased cBV/TV (OR: 0.67 [95% CI: 0.48-0.93], p value: 0.018) had lower odds of experiencing OA pain progression over the follow-ups.
Measurement of certain "conventional" MRI-based subchondral trabecular biomarkers has high reliability and modest validity. Though modest, there are significant associations between these biomarker changes and knee OA pain progression up to 48-month follow-up.
• Despite the lower spatial resolution than what is required to accurately study the subchondral trabecular microstructures, the "conventional" IW MRI sequences may retain adequate information that allows quantification of trabecular microstructure biomarkers. • Subchondral trabecular biomarkers obtained from "conventional" IW MRI sequences (i.e., cTbTh, cTbSp, and cBV/TV) are reliable and valid measures of trabecular microstructure changes compared to those from "apparent" trabecular biomarkers (from the FISP MRI sequence) and peri-articular BMD (from DXA). • Increased trabecular thickness and bone-to-total ratio (cTbTh and cBV/TV, obtained from "conventional" IW MRI sequences) from baseline to 24-month visits may be associated with higher odds of knee OA pain progression over 48 months of follow-up.
评估在“传统”中等加权(IW)MRI序列中测量软骨下骨小梁生物标志物的可靠性和有效性,并评估生物标志物变化对预测膝关节骨关节炎(OA)近期症状和结构进展的预测价值。
在本研究中,开发了一种在“传统”IW MRI序列中测量胫骨近端内侧骨小梁生物标志物的框架。在骨附属研究(骨关节炎倡议[OAI]内)中评估了测量这些生物标志物(骨小梁厚度[cTbTh]、间距[cTbSp]、连接密度[cConnD]和骨体积与总体积比[cBV/TV])的可靠性。通过与“表观”生物标志物(来自高分辨率稳态MRI序列)和关节周围骨髓密度(BMD,来自双能X线吸收法)进行比较,评估了这些测量的有效性。在FNIH OA生物标志物联盟(OAI内)中研究了这些生物标志物从基线到24个月(使用可靠变化指数)的变化与膝关节OA进展的关联。通过比较基线WOMAC疼痛评分和放射学关节间隙宽度与24至48个月的评分/测量值,评估疼痛和放射学进展。使用针对相关协变量进行调整的逻辑回归研究生物标志物变化与这些结果之间的关联。
在可接受的可靠性下,cTbTh和cBV/TV与“表观”生物标志物和关节周围BMD有适度关联,但cTbSp或cConnD没有(β:1.10 [95% CI:0.45 - 1.75],p值:0.001;β:3.69 [95% CI:2.56 - 4.83],p值:< 0.001)。cTbTh增加的膝关节有更高的(OR:1.44 [95% CI:1.03 - 2.02],p值:0.035),而cTbTh降低的膝关节(OR:0.69 [95% CI:0.49 - 0.95],p值:0.026)或cBV/TV降低的膝关节(OR:0.67 [95% CI:0.48 - 0.93],p值:0.018)在随访期间发生OA疼痛进展的几率较低。
某些基于“传统”MRI的软骨下骨小梁生物标志物的测量具有高可靠性和适度有效性。尽管这种关联适度,但在长达48个月的随访中,这些生物标志物变化与膝关节OA疼痛进展之间存在显著关联。
• 尽管空间分辨率低于准确研究软骨下骨小梁微结构所需的分辨率,但“传统”IW MRI序列可能保留了足够的信息,允许对骨小梁微结构生物标志物进行量化。• 与来自“表观”骨小梁生物标志物(来自FISP MRI序列)和关节周围BMD(来自DXA)相比,从“传统”IW MRI序列获得的软骨下骨小梁生物标志物(即cTbTh、cTbSp和cBV/TV)是骨小梁微结构变化的可靠且有效的测量指标。• 从基线到24个月随访期间,骨小梁厚度和骨体积与总体积比(cTbTh和cBV/TV,从“传统”IW MRI序列获得)增加可能与48个月随访期间膝关节OA疼痛进展的较高几率相关。